Safety and Efficacy of Over-the-counter Drug Use by the Elderly: Hearing Before the Subcommittee on Health and Long-Term Care of the Select Committee on Aging, House of Representatives, Ninety-eighth Congress, First Session, July 21, 1983 |
Other editions - View all
Common terms and phrases
advertising AGE AGE COUNT AGE COSTART CAUSE-EFFECT AGE COUNT amphetamine appetite suppressant caffeine Chairman clinical consumer CONTAINING DRUGS AGE COSTART CAUSE-EFFECT RELATIONSHIP COSTART COUNT 55 COSTART COUNT COSTART COUNT 28 COUNT COSTART COUNT CSPI diet aids diet pills diethylpropion doctor dosage double-blind Drug Administration DRUG AND REACTION drug products drug treatment DRUGS AGE COSTART efficacy elderly ephedrine ESTABLISHED WITH CERTAINTY evaluation Food and Drug Funderburk hearing hypertension ingestion ingredients L-carnitine labeling LANTOS look alikes mazindol medicine NSD NSD OAKAR obesity OTC drugs over-the-counter drugs OVERDOSE overweight Panel patients percent pharmacist phenylpropanolamine physician placebo pounds PPA CONTAINING DRUGS prescription drugs problem products containing PPA propanolamine pulse recommended reported response risk safe and effective safety side effects SILVERMAN SOMNOLENCE statistically subjects Supine sustained release systolic taking TOTAL OCCURRENCES unsafe URTICARIA Washington weeks weight control products weight loss Winick Zoloth
Popular passages
Page 99 - Associate Professor of Medicine at the Johns Hopkins University School of Medicine and Chief of Medicine at the Greater Baltimore Medical Center.
Page 175 - Geisser, S., & Greenhouse, SW An extension of Box's results on the use of the F distribution in multivariate analysis.
Page 349 - Self-medication with proprietary drugs is a significant factor in the US health care scheme. Escalating costs of health care create a greater need for low cost selfmedication than ever before. Seventy-five percent of all illnesses and injuries are initially treated through self-care and OTC medications. If only a small percentage of selftreatment was shifted to medical practitioners, the patient load would disrupt the US health care system.
Page 54 - Copies of the permanent injunctions and orders are available from the FTC's Public Reference Branch, Room 130, 6th Street and Pennsylvania Avenue, NW, Washington, DC 20580; 202-326-2222; TTY 202-326-2502.
Page 58 - This act shall take effect on the first day of September next succeeding the date on which it shall have become a law.
Page 99 - drug use" Implies the street use of stimulants or depressants, It will be so stated. The final judgment as to the efficacy of a drug is based on the benefits derived from the drug In contrast to the risks Inherent In the use of the drug. This is frequently spoken of as the risk-benefit ratio. If there are no great benefits to be derived from the use of a pharmaceutical agent, there would seem to be little justification for the use of this agent since some risk is inherent In the use of any foreign...
Page 7 - Mr. Regula. STATEMENT OF REPRESENTATIVE RALPH REGULA Mr. REGULA. Thank you, Mr. Chairman. I ask unanimous consent to make my statement a part of the record.
Page 477 - Act, by regulation, standards for the special packaging of any household substance if he finds that— (1) the degree or nature of the hazard to children in the availability of such substance, by reason of its packaging, is such that special packaging is required to protect children from serious personal injury or serious illness resulting from handling, using, or ingesting such substance ; and (2) the special packaging to be required by such standard is technically feasible, practicable, and appropriate...
Page 299 - ... (B) because of its toxicity or other potentiality for harmful effect, or the method of its use. or the collateral measures necessary to its use, is not safe for use except under the supervision of a practitioner licensed by law to administer such drug...
Page 334 - ... review of the OTC market. However, since a substantial proportion of the prescription drugs in the NAS-NRC review were also found to lack adequate evidence of effectiveness, the Agency decided that implementation of the prescription drug study should take priority over the review of OTC drug products. In deciding how to conduct the OTC drug review, the Agency had two choices: It could review each of the OTC products individually and move by separate court actions against each product alleged...